# 05-001: Treatment of Acute Lymphoblastic Leukemia in Children

> **NCT00400946** · PHASE3 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 800 (actual)

## Conditions studied

- Drug/Agent Toxicity by Tissue/Organ
- Leukemia

## Interventions

- **DRUG:** asparaginase
- **DRUG:** cyclophosphamide
- **DRUG:** cytarabine
- **DRUG:** dexamethasone
- **DRUG:** dexrazoxane hydrochloride
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** etoposide
- **DRUG:** leucovorin calcium
- **DRUG:** mercaptopurine
- **DRUG:** methotrexate
- **DRUG:** methylprednisolone
- **DRUG:** pegaspargase
- **DRUG:** prednisolone
- **DRUG:** therapeutic hydrocortisone
- **DRUG:** vincristine sulfate
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00400946
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2014-08
- **Final completion:** 2019-06
- **Target enrollment:** 800 (ACTUAL)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00400946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00400946, "05-001: Treatment of Acute Lymphoblastic Leukemia in Children". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT00400946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*